RS 09 is a TLR4 agonist for immune response research
**Background**
Toll-like receptor 4 (TLR4) is a critical pattern recognition receptor that plays a pivotal role in the innate immune system by recognizing lipopolysaccharide (LPS) from Gram-negative bacteria. Upon activation, TLR4 triggers a complex signaling cascade that leads to the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), resulting in the production of pro-inflammatory cytokines and the orchestration of adaptive immune responses. Due to its ability to enhance antigen-specific immunity, TLR4 agonists are of significant interest as vaccine adjuvants to improve the efficacy of immunizations against various pathogens and tumors. In this context, we will introduce a synthetic LPS peptide mimic and TLR4 agonist – RS 09.
**Definition**
RS 09 is a TLR4 agonist and LPS peptide mimic with a molecular weight of 805.80 and the chemical formula C33H50F3N9O11.
**In Vitro and In Vivo Studies**
The RS 09 description highlights its ability to bind to TLR4 and activate the NF-κB pathway. In terms of RS 09 in vitro activity, treatment with RS 09 (1-10 μg/mL; 24 h) stimulates TLR4 and activates NF-κB in HEK-BLUETM-4 cells. Furthermore, in RAW264.7 cells, RS 09 (5 μg/mL; 15 min-24 h) binds to TLR4, inducing the nuclear translocation of NF-κB and the secretion of inflammatory cytokines. Western blot analysis in RAW264.7 cells treated with 5 μg/mL of the compound showed increased nuclear NF-κB levels at 15, 30, 60, and 120 minutes.
Regarding RS 09 In Vivo application, the compound has been utilized as an adjuvant to co-immunize BALB/c mice with the prostate-cancer-specific antigen X-15 (conjugated to KLH). The results demonstrated that RS 09 can significantly increase the concentration of X-15-specific antibodies in mice, confirming its potential to enhance antigen-specific immune responses. For researchers seeking detailed RS 09 technical information, these findings suggest that the peptide mimic effectively replicates the immunostimulatory effects of LPS without the associated toxicity of bacterial endotoxins. In conclusion, RS 09 is a potent TLR4 agonist that functions as an effective adjuvant for enhancing immune responses.
Keywords
RS 09, RS09, RS-09, Toll-like Receptor (TLR), NF-κB, Nuclear factor-κB, Nuclear factor-kappaB, LPS, peptide, mimic, TLR4, vaccine, HEK-BLUETM-4, RAW264.7, Inhibitor, inhibitor, inhibit
References
**Background**
Neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s disease, as well as acute injuries like cerebral ischemia-reperfusion and influenza-induced pneumonia, are characterized by excessive oxidative stress, mitochondrial dysfunction, and severe inflammatory responses. The activation of pro-apoptotic proteins (e.g., Bax, p53, and caspase-3) and the triggering of the NF-κB signaling pathway often lead to irreversible neuronal loss and tissue damage. Finding agents that can simultaneously suppress inflammation and preserve mitochondrial integrity is crucial for developing effective therapeutic strategies. In this context, we will introduce a potent triterpenoid saponin monomer – Polygalasaponin F.
**Definition**
Polygalasaponin F is an orally active triterpenoid saponin monomer that exerts neuroprotective and anti-inflammatory effects by modulating the PI3K/Akt and NF-κB signaling pathways.
**In Vitro and In Vivo Studies**
The Polygalasaponin F biological activity is characterized by its ability to enhance cell viability and suppress apoptosis across various models. Polygalasaponin F in vitro studies demonstrate that at concentrations of 0.1-10.0 μM for 24-48 h, it increases the survival rate of rotenone-damaged PC12 cells, reduces the Bax/Bcl-2 ratio, and inhibits caspase-3 activation. In primary rat cortical neurons subjected to oxygen-glucose deprivation/reoxygenation (OGD/R), it activates the PI3K/Akt pathway and increases cell viability. Furthermore, in BV-2 microglia, Polygalasaponin F (0.1-10 μM) dose-dependently inhibits LPS-induced TNF-α secretion and NO production by reducing p65 nuclear translocation and inhibiting p38 MAPK phosphorylation. In hippocampal neurons, it blocks glutamate-induced Ca2+ overload and restores the expression of pCREB and BDNF. Additionally, it protects HT22 mouse hippocampal neurons against OGD/R injury by inhibiting excessive Polygalasaponin F Autophagy (specifically mitophagy) and alleviating oxidative stress.
Polygalasaponin F in vivo data further support its therapeutic potential. In BALB/c mice with influenza A (H1N1) induced pneumonia, oral administration (50-200 mg/kg once daily for 5-7 days) reduced pulmonary inflammatory responses, viral load, and body weight loss. In male KM mice, intraperitoneal injection (15-30 mg/kg once daily for 10 days) dose-dependently alleviated cerebral ischemia-reperfusion injury, with 30 mg/kg reducing cerebral infarct volume by approximately 55% while blocking excessive mitophagy. In conclusion, Polygalasaponin F is a multifunctional triterpenoid saponin that protects against neuronal injury and systemic inflammation.
Keywords
Polygalasaponin F, 882664-74-6, Toll-like Receptor (TLR), PI3K, Akt, NF-κB, MDM-2/p53, Caspase, MEK, Bcl-2 Family, p38 MAPK, Mitophagy, Reactive Oxygen Species (ROS), Apoptosis, Calcium Channel
References
[1] Wu MM, et al. Polygalasaponin F against rotenone-induced apoptosis in PC12 cells via mitochondria protection pathway. J Asian Nat Prod Res. 2014 Jan;16(1):59-69.
[2] Xie W, et al. Polygalasaponin F inhibits neuronal apoptosis induced by oxygen-glucose deprivation and reoxygenation through the PI3K/Akt pathway. Basic Clin Pharmacol Toxicol. 2020;127(3):196-204.
[3] Wei W, et al. Polygalasaponin F inhibits secretion of inflammatory cytokines via NF-κB pathway regulation. J Asian Nat Prod Res. 2014;16(8):865-75.
[4] Yan WF, et al. The molecular mechanism of polygalasaponin F-mediated decreases in TNFα: emphasizing the role of the TLR4-PI3K/AKT-NF-κB pathway. J Asian Nat Prod Res. 2015;17(6):662-70.
[5] Ye Y, et al. Polygalasaponin F treats mice with pneumonia induced by influenza virus. Inflammopharmacology. 2020;28(1):299-310.
[6] Sun C, et al. Polygalasaponin F protects hippocampal neurons against glutamate-induced cytotoxicity. Neural Regen Res. 2022;17(1):178-184.
[7] Quan S, et al. Polygalasaponin F alleviates cerebral ischemia-reperfusion injury through inhibiting mitophagy. Metab Brain Dis. 2025;40(8):296. Published 2025 Oct 24.
**Background**
The proteasome is a large multi-subunit protease complex responsible for the degradation of ubiquitinated proteins, playing a critical role in maintaining cellular protein homeostasis. Dysregulation of the ubiquitin-proteasome system is frequently observed in various pathologies, particularly in cancer, where the degradation of tumor suppressors or the stabilization of oncoproteins drives malignancy. By inhibiting the proteasome, it is possible to block the degradation of key regulatory proteins, such as p53, thereby triggering programmed cell death. Given its ability to modulate protein turnover and induce apoptosis, the proteasome has become a primary target for therapeutic intervention in MG-115 cancer research. In this context, we will introduce a potent and reversible proteasome inhibitor – MG-115.
**Definition**
MG-115 is a reversible proteasome inhibitor that specifically targets the chymotrypsin-like activity of the proteasome, exhibiting $K_i$ values of 21 nM for the 20S proteasome and 35 nM for the 26S proteasome.
**In Vitro Studies**
According to the MG-115 description, this compound is designed to inhibit proteasomal activity and induce p53-dependent apoptosis. In terms of MG-115 biological activity, in vitro studies have demonstrated its efficacy in various cellular models. Specifically, MG-115 (0.1-10 μM; 24 h) was found to decrease the viability of HepG2 cells in a dose-dependent manner, with an $\text{IC}_{50}$ of 2 μM for the inhibition of proteasomal activity. Furthermore, treatment with MG-115 (0.1-10 μM; 24 h) has been shown to amplify reporter gene expression mediated by CWK 18 DNA condensates. These results highlight the compound’s ability to modulate cellular viability and gene expression by targeting the proteasome pathway. In conclusion, MG-115 is a potent and reversible proteasome inhibitor suitable for studying protein degradation and apoptosis.
Keywords
MG-115, 133407-86-0, MG115, MG 115, Proteasome, Apoptosis, 20S, 26S, apoptosis, Inhibitor, inhibitor, inhibit
References
[1] Rock KL, et, al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994 Sep 9;78(5):761-71.
[2] Lopes UG, et, al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997 May 16;272(20):12893-6.
[3] Kim J, et, al. The proteasome metabolizes peptide-mediated nonviral gene delivery systems. Gene Ther. 2005 Nov;12(21):1581-90.
**Background**
Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that plays a critical role in regulating glucose metabolism, lipid storage, and inflammatory responses. Dysregulation of PPARγ is closely linked to the development of insulin resistance and type 2 diabetes. Furthermore, the modulation of intracellular calcium ([Ca²⁺]i) levels is a fundamental mechanism in various pathological processes, including inflammation and malignancy. In particular, the mobilization of calcium from the endoplasmic reticulum and the promotion of extracellular calcium influx are key targets for treating inflammatory diseases and certain types of bladder cancer. In this context, we will introduce a selective PPARγ ligand and anti-inflammatory agent – Fmoc-leucine.
**Definition**
Fmoc-leucine (N-FMOC-leucine) is a selective ligand for PPARγ with a Ki value of 15 μM. It functions as an anti-inflammatory agent that promotes both extracellular Ca²⁺ influx and intracellular Ca²⁺ release.
**In Vitro and In Vivo Studies**
According to the Fmoc-leucine description, this compound exhibits unique self-assembly properties, allowing it to form transient gels, stable gels, or 2D sheets. In terms of Fmoc-leucine in vitro activity, treatment with 1 mM Fmoc-leucine for 24 hours significantly enhances the interaction between PPARγ and SRC-1 in RK13 cells. In 3T3-L1 cells, Fmoc-leucine (10 μM; 0-6 days) induces the expression of LPL and aP2, although its lipid accumulation capacity is significantly lower than that of Rosiglitazone. Furthermore, Fmoc-leucine (0.1-2 mM) increases [Ca²⁺]i in MDCK and BFTC cells in a concentration-dependent manner, with an EC50 of 0.5 mM in MDCK cells. In BFTC bladder cancer cells, it specifically induces Ca²⁺ release from the endoplasmic reticulum and activates Ca²⁺ influx.
Regarding Fmoc-leucine in vivo data, administration of 10-60 mg/kg (i.p.; once daily for 7 or 14 days) improves glucose tolerance in normal mice as well as in diet-induced insulin resistance and db/db diabetic models, showing a synergistic effect when combined with Rosiglitazone. Additionally, Fmoc-leucine (50 mg/kg; i.p.; once daily for 4 days) reduces the severity of TNBS-induced colitis in C57BL/6J mice. These results highlight the potential of the compound in treating metabolic disorders and inflammatory conditions. In conclusion, Fmoc-leucine is a selective PPARγ ligand with potent insulin-sensitizing and anti-inflammatory properties.
Keywords
Fmoc-leucine, 35661-60-0, N-FMOC-leucine, NPC 15199, NSC 334290, NPC15199, NPC-15199, NSC334290, NSC-334290, PPAR, Calcium Channel, Lipase, Peroxisome proliferator-activated receptors
References
[1] Rocchi S, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell. 2001 Oct;8(4):737-47.
[2] Paul S, et al. Complex Pathways Drive Pluripotent Fmoc-Leucine Self-Assemblies. Angew Chem Int Ed Engl. 2024 Sep 9;63(37):e202406220.
[3] Jan CR, Yu CC, Huang JK. NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells. Chin J Physiol. 2000 Mar 31;43(1):29-33.
[4] Jan CR, et al. Effect of NPC-15199 on Ca2+ levels in renal tubular cells. Chin J Physiol. 2002 Sep 30;45(3):117-22. Erratum in: Chin J Physiol. 2003 Dec 31;45(4):200.
**Background**
The C-X-C chemokine receptor type 4 (CXCR4) and its ligand, CXCL12, play a critical role in the homing, retention, and mobilization of hematopoietic stem/progenitor cells (HSPCs) within the bone marrow niche. The CXCR4/CXCL12 axis is a primary regulator of the bone marrow microenvironment, and its disruption is essential for the mobilization of stem cells into the peripheral blood. This process is clinically vital for autologous hematopoietic stem cell transplantation (ASCT), particularly in patients with multiple myeloma and lymphoma. By antagonizing this pathway, researchers can enhance the collection of CD34+ cells for therapeutic use. In this context, we will introduce a potent CXCR4 antagonist – Burixafor.
**Definition**
Burixafor (TG-0054) hydrobromide is a potent CXCR4 antagonist and inverse agonist with a pIC50 of 7.4.
**In Vitro and In Vivo Studies**
According to the Burixafor description, this compound inhibits the binding of CXCL12 to CXCR4, antagonizes the recruitment of Gαᵢ and β-arrestin2, and blocks downstream Gαᵢ-mediated inhibitory effects on cAMP signal transduction. In terms of Burixafor in vitro activity, the compound potently displaces CXCL12 from CXCR4 on HEK293 cells stably expressing SNAP-CXCR4 (pIC50 = 7.4). In transiently transfected HEK293 cells, it inhibits CXCL12-induced recruitment of miniGαᵢ (pIC50 = 7.7) and β-arrestin2 (pIC50 = 8.0). Furthermore, it reverses CXCR4-dependent inhibition of cAMP in HEK293 cells (pIC50 = 7.9) and acts as a potent inverse agonist on the constitutively active CXCR4 N119S mutant (pIC50 = 7.5).
Regarding Burixafor in vivo efficacy, the compound has demonstrated the ability to mobilize mesenchymal stem cells, reduce inflammation, and maintain cardiac systolic function in porcine myocardial infarction models. In a Mycophenolate-treated swine heart transplant model, it suppressed cardiac allograft vasculopathy and decreased the incidence of acute rejection. Additionally, Burixafor mobilizes HSPCs in mice, showing enhanced efficacy when co-administered with Propranolol. In conclusion, Burixafor is a potent CXCR4 antagonist that facilitates the mobilization of hematopoietic stem/progenitor cells and holds significant potential for research in ASCT and inflammatory cardiac conditions.
Keywords
Burixafor, 1191450-19-7, TG-0054, TG0054, TG 0054, CXCR, CXC chemokine receptors, C-X-C motif chemokine receptors, Inhibitor, inhibitor, inhibit
References
[1] Pan KS, et al. Pharmacological characterization of a clinical candidate, TG-0054, a small molecule inverse agonist targeting CXCR4. Mol Pharmacol. 2025;107(4):100015.
[2] Sukhtankar DD, et al. Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplant. Ann Hematol. 2026;105(3):86. Published 2026 Feb 4.
**Background**
Chronic kidney disease (CKD) is a progressive condition characterized by the gradual loss of kidney function, which often leads to the accumulation of potassium in the blood, a condition known as hyperkalemia. Hyperkalemia is a potentially life-threatening complication that can cause cardiac arrhythmias and cardiac arrest, necessitating efficient and selective methods for potassium removal. Traditional potassium binders often lack selectivity or cause gastrointestinal distress. Therefore, there is a critical need for novel inorganic compounds that can selectively trap excess potassium ions in the gastrointestinal tract without affecting other essential electrolytes. In this context, we will introduce a highly selective cation exchanger – Sodium zirconium cyclosilicate.
**Definition**
Sodium zirconium cyclosilicate (also known as ZS-9) is an orally administered, non-absorbed, inorganic microporous zirconium silicate compound that functions as a selective cation exchanger to remove excess K+ in vivo.
**In Vitro and In Vivo Studies**
According to the Sodium zirconium cyclosilicate description, this compound is an inorganic cation exchange crystalline compound with a high capacity to selectively entrap monovalent cations, specifically excess K+ and ammonium ions. Sodium zirconium cyclosilicate in vitro studies demonstrate that the exchange capacities for divalent ions such as Ca2+ and Mg2+ are below 0.05 mEq/g, showing a >25-fold selectivity for K+ over either Ca2+ or Mg2+. For researchers seeking Sodium zirconium cyclosilicate technical information regarding preparation, it can be formulated as a 1 mg/mL suspension in water as a stock solution and stored at -80°C. As an insoluble inorganic crystal, it adsorbs potassium ions through an ion exchange mechanism rather than dissolution.
Sodium zirconium cyclosilicate In Vivo studies were conducted using Sprague-Dawley rats to evaluate its efficacy in potassium removal. When administered orally at dosages of 2, 4, and 6 g/kg daily for 5 days, the compound demonstrated a dose-dependent uptake and removal of potassium ions. Furthermore, the treatment resulted in 99% fecal recovery in the rat models, confirming that the compound remains non-absorbed in the gastrointestinal tract while effectively clearing potassium. In conclusion, Sodium zirconium cyclosilicate is a highly selective, non-absorbed inorganic ion trap that holds significant promise for the management of hyperkalemia in chronic kidney disease research.
Keywords
Sodium zirconium cyclosilicate, 17141-74-1, Biochemical Assay Reagents, Inorganic, microporous, zirconium silicate compound, potassium ion, cation exchanger, chronic kidney disease, Inhibitor, inhibitor, inhibit
References
[1] Stavros F, et, al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014 Dec 22;9(12):e114686.
[2] Ash SR, et, al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015 Aug;88(2):404-11.
**Background**
Platelet-derived growth factor receptors (PDGFRs) are transmembrane tyrosine kinases that play critical roles in cell proliferation, migration, and survival. Dysregulation of these receptors is implicated in various pathological conditions, including fibrosis and neurodegenerative diseases. In particular, the modulation of kinase signaling pathways has become a focal point in the study of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by the loss of motor neurons. Targeting multiple kinases simultaneously may provide a more comprehensive therapeutic approach than single-target inhibition. In this context, we will introduce a multikinase inhibitor – PDGFR Tyrosine Kinase Inhibitor III.
**Definition**
PDGFR Tyrosine Kinase Inhibitor III is a multikinase inhibitor that targets PDGFR, EGFR, FGFR, PKA, and PKC. According to the PDGFR Tyrosine Kinase Inhibitor III description, this compound serves as a potent tool for investigating kinase-mediated signaling pathways in various cellular models.
**In Vitro Studies**
The PDGFR Tyrosine Kinase Inhibitor III biological activity has been evaluated across different cell lines to determine its inhibitory potency. In CHO cells, the compound demonstrated an IC50 value of > 0.08 μM against platelet-derived growth factor receptor beta phosphorylation. Furthermore, in porcine aorta smooth muscle cells (PASMC), PDGFR Tyrosine Kinase Inhibitor III exhibited an IC50 of 0.25 μM in the inhibition of PDGF-BB-induced proliferation. For researchers requiring precise experimental parameters, the PDGFR Tyrosine Kinase Inhibitor III protocol provides guidance on its application in these assays. The compound possesses a molecular weight of 485.53 and a specific chemical structure defined by the PDGFR Tyrosine Kinase Inhibitor III Formula (C27H27N5O4). In conclusion, PDGFR Tyrosine Kinase Inhibitor III is a versatile multikinase inhibitor suitable for the research of amyotrophic lateral sclerosis and other kinase-related pathologies.
Keywords
PDGFR Tyrosine kinase-IN-1, 205254-94-0, PDGFR, Platelet-derived growth factor receptor, multikinase inhibitor, EGFR, FGFR, PKA, PKC, Inhibitor, inhibitor, inhibit
References
**Background**
Metabolic disorders, such as diabetes, and various forms of cancer remain significant global health challenges. In the context of metabolic health, the activation of the insulin signaling pathway is critical for glucose homeostasis and the regulation of adiponectin secretion. Simultaneously, the development of chemopreventive agents that can selectively induce apoptosis in malignant cells while sparing non-tumorigenic cells is a primary goal of oncology research. Natural flavonoids have gained attention due to their diverse pharmacological properties, including anti-inflammatory and antitumoral effects. Therefore, we will introduce a natural flavonoid with potent biological activities – Kaempferitrin.
**Definition**
Kaempferitrin is a natural flavonoid and polyphenol with the Kaempferitrin formula C27H30O14, known for its antinociceptive, anti-inflammatory, anti-diabetic, and antitumoral effects.
**In Vitro and In Vivo Studies**
The Kaempferitrin biological activity has been extensively studied in both metabolic and oncological models. In vitro, Kaempferitrin activates the insulin signaling pathway in matured 3T3-L1 adipocytes, maintaining survival rates above 90% at concentrations of 1-20 μM. At 15 μM, it increases insulin receptor beta tyrosine phosphorylation and tyrosine phosphorylation of the insulin receptor substrate 1, mirroring the effects of 10 nM insulin. Furthermore, Kaempferitrin (15 μM) stimulates Akt phosphorylation on Ser473 and promotes the translocation of GLUT4 to the adipocyte membrane, both of which are suppressed by the PI3-K inhibitor wortmannin. It also increases total Glu4 protein levels and secreted adiponectin in these cells.
Regarding Kaempferitrin Cancer research, the compound exhibits selective cytotoxicity toward human cancer cells. In HeLa and MDA-MB231 cells, it shows IC50 values of 45 ± 2.6 and 65 ± 2.6 μM, respectively, with low toxicity toward non-tumorigenic cells. Specifically, Kaempferitrin (45 μM) induces G1 arrest, activates caspase 3, and triggers the intrinsic pathway of apoptosis and ROS generation in HeLa cells. Kaempferitrin in vivo studies further demonstrate its potency; in nu/nu mice bearing HeLa tumors, administration of 2.5, 10, and 25 mg/kg (i.p.) markedly suppressed tumor growth by 40%, 87%, and 97%, and decreased tumor weight by 37%, 81%, and 95%, respectively. Additionally, it inhibited cell proliferation and extended the lifespan of tumor-bearing mice. In conclusion, Kaempferitrin is a multifunctional flavonoid that serves as a potent activator of insulin signaling and a selective antitumor agent.
Keywords
Kaempferitrin, 482-38-2, Lespedin, Lespenephryl, Insulin Receptor, Inhibitor, inhibitor, inhibit
References
[1] Tzeng YM, et al. Kaempferitrin activates the insulin signaling pathway and stimulates secretion of adiponectin in 3T3-L1 adipocytes. Eur J Pharmacol. 2009 Apr 1;607(1-3):27-34.
[2] Alonso-Castro AJ, et al. Kaempferitrin induces apoptosis via intrinsic pathway in HeLa cells and exerts antitumor effects. J Ethnopharmacol. 2013 Jan 30;145(2):476-89.
**Background**
Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperplasia and the infiltration of immune cells. The pathogenesis of this condition is heavily driven by the IL-23/IL-17 axis, where the transcription factor retinoic acid-related orphan receptor gamma t (RORγt) serves as the master regulator. RORγt is essential for the differentiation of TH17 cells and the subsequent production of pro-inflammatory cytokines, including IL-17 and IL-22. Because of its central role in orchestrating the inflammatory response, RORγt has become an attractive therapeutic target for the treatment of various inflammatory diseases, particularly chronic plaque psoriasis. In this context, we will introduce an orally active RORγt inverse agonist – Cedirogant.
**Definition**
Cedirogant (ABBV-157) is an orally active RORγt inverse agonist with the molecular formula C24H20Cl3F3N2O3.
**In Vitro Studies**
According to the Cedirogant description, this compound is designed to inhibit the activity of RORγt to suppress the differentiation of TH17 cells. In terms of Cedirogant in vitro activity, the compound targets the RORγt transcription factor to reduce the production of IL-17 and IL-22, which are key drivers of the inflammatory cascade in skin tissues. Research indicates that Cedirogant has significant potential for the study of chronic plaque psoriasis by modulating these pathways. For researchers requiring specific Cedirogant technical information regarding its chemical properties, it possesses a molecular weight of 547.78 and is identified by CAS No. 2055496-11-0. In conclusion, Cedirogant is a potent RORγt inverse agonist that holds promise as a tool for investigating the pharmacological management of inflammatory diseases and psoriasis.
Keywords
Cedirogant, 2055496-11-0, ABBV-157, ABBV157, ABBV 157, ROR, RAR-related orphan receptor, RORγt, inverse, agonist, psoriasis, Inhibitor, inhibitor, inhibit
References
[1] Elena Campione, et al. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021 Jul 26;13:725-737.
[2] Christian Gege. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently? Expert Opin Drug Discov. 2021 Jul 7;1-19.
The identification and management of aberrant left hepatic arteries (ALHAs) during gastrectomy remain a critical challenge in minimally invasive upper gastrointestinal surgery. ALHAs, which originate from the left gastric artery rather than the standard hepatic arterial tree, are present in up to 34% of patients and may serve as the primary blood supply to segments 2, 3, and 4 of the left lobe. Their inadvertent ligation during D2 lymphadenectomy can lead to postoperative liver ischemia, dysfunction, or necrosis—particularly when they function as replacement arteries. Preoperative imaging modalities such as CT angiography often fail to accurately define the functional significance of these variants, leaving surgeons reliant on anatomical assumptions.
This study evaluates the intraoperative utility of indocyanine green (ICG)-enhanced near-infrared fluorescence imaging (NIRFI) for real-time assessment of hepatic perfusion during laparoscopic and robotic gastrectomy. A retrospective analysis was conducted on 31 consecutive patients with gastric adenocarcinoma who underwent radical gastrectomy between May 2018 and August 2019. All patients had normal preoperative liver function and were free from cirrhosis, prior hepatic surgery, or abnormal liver enzyme levels. An ALHA was identified via laparoscopic exploration under NIRFI, and its origin was confirmed at the root of the left gastric artery.
After clamping the suspected ALHA near the left hepatic lobe, 5 mg of ICG dissolved in 2 mL sterile water was administered intravenously. Fluorescence patterns were visualized using either the PINPOINT® system (Stryker) or the Firefly® module integrated into the da Vinci Xi® robotic platform. The Color Segmented Fluorescence mode was employed to assess perfusion gradients, with gray indicating no flow and red representing high perfusion.
Fluorescence became visible on average 43 seconds after injection (range: 25–65 s). In 20 patients (64.Atazanavir medchemexpress 5%), strong and uniform fluorescence was observed across the entire liver surface, indicating that the ALHA was accessory and could be safely ligated. In 11 patients (35.5%), partial or absent fluorescence was detected along the left lobe, suggesting the ALHA supplied essential hepatic segments. These cases underwent unclamping and a second ICG injection. Restoration of fluorescence confirmed adequate collateral circulation, allowing preservation of the vessel in 10 patients. One patient required ligation due to technical constraints despite initial perfusion deficit.
No adverse events related to ICG administration were recorded, including allergic reactions, hemodynamic changes, or skin discoloration. All procedures were completed without conversion to open surgery or additional port placement. Mean operative time was 196.4 minutes (range: 97–278), with estimated blood loss of 82.3 mL (range: 10–286). Postoperative recovery was uncomplicated, with mean hospital stay of 7.4 days (range: 5–21). Liver enzymes showed transient elevations—AST peaked at 32.4 IU/L on the operation day and ALT at 33.3-Ethoxy-1-propanol Purity & Documentation 1 IU/L on postoperative day 2—but remained below two times the upper limit of normal.PMID:35143115 No patient required liver-protective medication, and no Clavien-Dindo grade III or higher complications were reported.
Pathological staging revealed stage I disease in 28 patients (90.4%), with a mean of 39.2 retrieved lymph nodes per case. There were no significant differences in surgical outcomes, blood loss, or hospital stay between patients whose ALHAs were preserved versus ligated. All patients who underwent ALHA preservation demonstrated stable postoperative liver function without evidence of ischemic injury.
This study demonstrates that ICG-enhanced NIRFI provides a safe, reliable, and real-time method for assessing hepatic perfusion during gastrectomy. It enables dynamic, function-based decision-making regarding ALHA management, reducing the risk of unnecessary ligation while maintaining oncologic safety. The technique is compatible with both laparoscopic and robotic platforms, requires minimal workflow disruption, and enhances surgical precision. Its integration into routine practice represents a significant advancement in managing vascular anomalies during gastrointestinal surgery. Future research should focus on standardizing protocols, validating findings in larger multicenter trials, and expanding application to other complex abdominal procedures involving vascular variations.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com